![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Teva Receives Approval for Generic Biaxin
Teva Receives Approval for Generic Biaxin
Teva Pharmaceutical has received final approval from the FDA for its abbreviated new drug application for clarithromycin extended-release tablets in a 500-mg dosage form.
Teva's tablets are the generic equivalent of Abbott's antibiotic Biaxin XL filmtabs. The brand product has annual sales of roughly $284 million, according to Teva.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct